Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen Adds Precautions for Concerta for Patients Over 18
September 19, 2011
- Takeda to Initiate Domestic PIII Trial for Once-weekly DPP-4 Inhibitor
September 19, 2011
- Perampanel Improves Partial Epilepsy Seizures in Overseas PIII Trial
September 19, 2011
- Zonegran Shows High Efficacy for Pediatric Partial Epilepsy: Eisai
September 19, 2011
- NanoCarrier Obtains Substance Patent for Its “pH-Responsive Micelle” in China
September 19, 2011
- Sales of Ethical Drugs Up 0.1% in July: Crecon & Research Consulting
September 19, 2011
- Sandoz to Use Its Unique Anticancer Drug Container for More Anticancer Drugs
September 19, 2011
- Nichi-Iko, Pfizer Apply for Add’l Indication for Generic Cisplatin Using Data from Public Domain
September 19, 2011
- Astellas, UMN Pharma Complete Cell Culture–based Flu Vaccine Inoculation of Subjects in PI/PII Trials
September 16, 2011
- OncoTherapy Completes Patient Enrolment for PII Trial of Angiogenesis Inhibitor
September 16, 2011
- Everolimus Obtains EU Approval for SEGA: Novartis
September 16, 2011
- Ono Pharmaceutical Licenses Ca Receptor Agonist from US Company
September 16, 2011
- Ono Licenses in Ion Channel Inhibitor Ivabradine from Servier
September 15, 2011
- Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
- Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
- JCR Revises Half-, Full-Year Business Forecasts for FY Ending March 2012
September 14, 2011
- DSP to End Sales of Melbin
September 14, 2011
- Medipal HD, JCR Announce Codevelopment Agreement for 3 Products
September 14, 2011
- FDA Advisory Committee Recommends Approval of Rivaroxaban for SPAF
September 13, 2011
- AZ, Daiichi Sankyo to Launch Nexium on Sept. 15
September 13, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…